CBD for Epilepsy: What the Clinical Trial Evidence Shows for Epidiolex
Epidiolex (pharmaceutical CBD) is the only cannabis-derived drug approved by the FDA and EMA for epilepsy, with proven efficacy for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex seizures.
Quick Facts
What This Study Found
CBD was isolated from cannabis in 1940 and has a confirmed anti-seizure effect without psychoactive activity. Epidiolex is the only cannabis-derived drug to complete clinical trials and gain FDA/EMA approval, specifically for Dravet syndrome, Lennox-Gastaut syndrome, and seizures associated with tuberous sclerosis complex.
Key Numbers
CBD isolated in 1940; Epidiolex is the only FDA/EMA approved cannabis-derived epilepsy drug; approved for Dravet, LGS, and TSC
How They Did This
Position paper reviewing the mechanism of CBD's anti-seizure action, completed clinical trials of Epidiolex, and current approved indications for CBD in epilepsy.
Why This Research Matters
As interest in cannabis-based treatments grows, it is important to distinguish between what is proven (Epidiolex for specific epilepsies) and what remains unproven (non-pharmaceutical CBD products for seizures).
The Bigger Picture
Epidiolex represents the most successful translation of cannabis science into regulated medicine. Its approval pathway could serve as a model for other cannabinoid medications.
What This Study Doesn't Tell Us
Position paper focused on pharmaceutical-grade CBD only. Does not address the growing use of non-pharmaceutical CBD products for seizures.
Questions This Raises
- ?Could CBD be effective for other epilepsy types beyond the three currently approved indications?
- ?How do non-pharmaceutical CBD products compare to Epidiolex in efficacy and safety?
Trust & Context
- Key Stat:
- Only FDA/EMA-approved cannabis-derived epilepsy drug
- Evidence Grade:
- Position paper summarizing completed randomized controlled trials that led to regulatory approval.
- Study Age:
- Published in 2022
- Original Title:
- Use of cannabidiol in the treatment of epilepsy.
- Published In:
- Neurologia i neurochirurgia polska, 56(1), 14-20 (2022)
- Authors:
- Mazurkiewicz-Bełdzińska, Maria(2), Zawadzka, Marta
- Database ID:
- RTHC-04050
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is CBD approved for treating epilepsy?
Epidiolex, a pharmaceutical-grade CBD, is the only cannabis-derived drug approved by both the FDA and EMA for epilepsy. It is specifically approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex seizures.
Does CBD work for all types of epilepsy?
CBD has proven efficacy for three specific epilepsy conditions (Dravet, LGS, TSC). Additional studies are needed to determine if it could help other forms of epilepsy.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04050APA
Mazurkiewicz-Bełdzińska, Maria; Zawadzka, Marta. (2022). Use of cannabidiol in the treatment of epilepsy.. Neurologia i neurochirurgia polska, 56(1), 14-20. https://doi.org/10.5603/PJNNS.a2022.0020
MLA
Mazurkiewicz-Bełdzińska, Maria, et al. "Use of cannabidiol in the treatment of epilepsy.." Neurologia i neurochirurgia polska, 2022. https://doi.org/10.5603/PJNNS.a2022.0020
RethinkTHC
RethinkTHC Research Database. "Use of cannabidiol in the treatment of epilepsy." RTHC-04050. Retrieved from https://rethinkthc.com/research/mazurkiewicz-beldzinska-2022-use-of-cannabidiol-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.